Nuveen Asset Management LLC Acquires 89,170 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Nuveen Asset Management LLC boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 43.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 292,645 shares of the company's stock after buying an additional 89,170 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.49% of Twist Bioscience worth $13,599,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 19.9% in the 4th quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock worth $206,000 after acquiring an additional 757 shares during the last quarter. KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Twist Bioscience by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,586 shares of the company's stock worth $585,000 after buying an additional 1,318 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after buying an additional 302,884 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on TWST shares. JPMorgan Chase & Co. dropped their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group cut their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Trading Up 2.2%

TWST stock traded up $0.63 on Friday, hitting $29.52. 1,250,070 shares of the company were exchanged, compared to its average volume of 980,937. Twist Bioscience Co. has a twelve month low of $27.12 and a twelve month high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The business's fifty day moving average is $35.28 and its two-hundred day moving average is $42.27. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -8.73 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. As a group, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $55,840.75. Following the completion of the sale, the chief operating officer now directly owns 240,783 shares of the company's stock, valued at $7,163,294.25. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 918 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,850 shares of company stock worth $974,764 over the last ninety days. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.